Anti-E-Cadherin (Human) LIMAAbody® #10005

Documentation:

• Download Datasheet

• Download MSDS

Product Information:

Applications tested
Immunofluorescence staining, wholemount tissue staining.

Specificity/Target
Human E-Cadherin. Validated on human tissue samples and cell lines. 

Type
Nanobody, single-domain antibody, VHH

Clone
Polyclonal: 2MEN28, 3MEN91, 3MEN141

Reactivity
Human. Reactivity based on IF and IHC stainings of tissue samples and cell lines.

Immunogen
Recombinant protein containing the extracellular domain of E-Cadherin protein.

Class
Recombinant, produced in E.coli.

Host
Alpaca

Sensitivity
Endogenous protein expression.

Conjugate
Unconjugated.
Suitable for conjugation of fluorescent dyes, biotin, beads, surfaces etc. via NHS ester chemistry.

VHH protein tag
C-terminal (6x)His-Tag

Purity
Affinity-purified antibody fragment.

Molecular Weight
2MEN28: 13,2 kDa
3MEN91: 13,2 kDa
3MEN141: 12,3 kDa

Form
Buffered solution.

Storage buffer
Phosphate buffered saline (PBS), pH=7,4; Preservative: 0.03% Sodium azide.

Storage condition
Shipped at ambient temperature. Upon receipt store at 4°C. Stable for 6 months. Do not freeze.

Product Usage Information
For optimal immunofluorescence staining results, use nanobody at concentrations between 10-30µg/ml in combination with recommended LIMAA reagents and protocols.

Application and Dilution
Immunofluorescence (frozen sections): 10 µg/ml
Immunofluorescence (cell culture): 5 µg/ml
lmmunofluorescence (wholemount tissue staining): 20 µg/ml

Background
E-Cadherin, a type I transmembrane glycoprotein encoded by the CDH1 gene, is a pivotal molecule involved in cell-cell adhesion and tissue organization. Functioning primarily in epithelial tissues, E-Cadherin mediates calcium-dependent homophilic interactions between adjacent cells, contributing to the formation and maintenance of adherens junctions. Through its cytoplasmic domain, E-Cadherin connects with the actin cytoskeleton via catenin proteins, providing structural integrity and facilitating intracellular signaling pathways crucial for cell polarity, migration, and differentiation. Dysregulation or loss of E-Cadherin expression is associated with disrupted tissue architecture, increased invasiveness, and metastasis in various cancers, highlighting its significance in both normal development and disease progression.

Trademarks and Patents
LIMAAbody® is a trademark of LIMAA Technologies GmbH.
ATTO is a registered trademark of ATTO-TEC GmbH.
All other trademarks are the property of their respective owners.

Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of LIMAA, the following terms apply to Products provided by LIMAA, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of LIMAA, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA, EMA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by LIMAA are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from LIMAA. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with LIMAA products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with LIMAAs terms of sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.